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Background
Interferon gamma is a licensed product for treating certain
immune deficiency diseases, but its use in people with
HIV is experimental. IFN- is normally made by CD4 T-
cells – the cells which are depleted in people with AIDS
and it has antineoplastic effects and antiviral activity
mediated by immunomodulatory effects. At a cellular
level these include macrophage activation, stimulation of
antigen presentation through class I and class II major his-
tocompatibility complex molecules, regulation of leuko-
cyte-endothelium interaction, and effects on cell
proliferation and apoptosis. It is therefore theorized that
giving HIV-positive people co-infected with TB supple-
mentary injections of interferon gamma may help boost
their immune response.
Objective
To obtain preliminary information on the safety, immu-
nologic and virologic effects of IFN-gamma in adults co-
infected with HIV and TB with immune reserve (CD4T-
cell count above 350 cells/ml) on TB medication but not
on antiretroviral therapy.
Materials and methods
51 HIV-infected persons newly diagnosed with active PTB
were recruited in the special HIV and TB unit of the second
city tuberculosis hospital in Saint Petersburg, Russia into
an observational, prospective study between March and
December 2005. All the patients had a median CD4 cell
count of above 350 cells/ml and were not previously on
HAART. 21 patients (41.2%), apart from standard TB
medication also received interferon gamma(γ-IFN) injec-
tion (Ingaron) at a dose of 500 000 i.u. subcutaneously
three times weekly for eight weeks, while the rest 30
(48.8%) received similar TB treatment plus placebo. They
were assessed clinically weekly, while laboratory investi-
gations were conducted at the initiation of therapy and at
weeks 4 and 8.
Results
Interim assessment of the outcome of TB treatment at 8
weeks of follow up showed a remarkable improvement of
clinical conditions and immunologic responses of the
patients receiving gamma interferon (Ingaron) as against
those in the control group. In general, γ-IFN therapy was
well tolerated. The major adverse event thought to be pos-
sibly  γ-IFN associated was low grade fever. Increase in
CD4+ lymphocyte counts and decrease in plasma HIV
RNA concentrations were observed in the study group.
CD4+ increased from 656.2 ± 41.3 to 728.4 ± 74.7 cells/
ml (p > 0.05) (table 1) while plasma RNA became unde-
tectable in 11 patients in the study group as against nil in
the control group.
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Conclusion
Gamma interferon therapy in patients co-infected with
HIV and tuberculosis receiving TB medications is safe,
improves clinical outcome and enhances host defense
mechanism. Larger studies will be needed to assess the
drug's long term clinical efficacy in the treatment of HIV-
associated complications such as PTB.